ライフサイエンスコーパス: primary antibody

1 ondary antibodies specific to each patterned primary antibody.

2 n blotting with a dinitrophenylated-specific primary antibody.

3 thin the retina using an anti-cGK I-specific primary antibody.

4 rmed by immunofluorescence using an anti-MCP primary antibody.

5 rmed by immunofluorescence using an antihook primary antibody.

6 econdary antibodies were added to bind these primary antibodies.

7 ng using patient sera/cerebrospinal fluid as primary antibodies.

8 secondary antibodies were then used to mark primary antibodies.

9 ific identifications and cross-reactivity of primary antibodies.

10 improve the utility of some poorly reactive primary antibodies.

11 sera of individual patients were tested for primary antibodies.

12 e stained with CTGF and TGF-beta1 polyclonal primary antibodies.

13 sis in which individual sera were tested for primary antibodies.

14 quitination than p53s with a more wild-type (primary antibody 1620+/pAb240-) conformation.

15 rved that cancer-derived p53s with a mutant (primary antibody 1620-/pAb240+) conformation localized i

16 munolabeled by incubation overnight with the primary antibodies 7G6, a cone-specific antibody; SV2, a

17 chemically by simultaneous staining with two primary antibodies: a phospho-specific primary and norma

18 he surface area to capture a large amount of primary antibodies (Ab1), thus amplifying the detection

19 ever, our optimization of cholesterol level, primary antibody affinity, and antibody-bead linkage all

20 To understand the importance of primary antibody affinity, we compared a series of point

21 Primary antibodies against inflammatory and proangiogeni

22 sections by using double immunolabeling with primary antibodies against Muller and other retina-speci

23 processed by immunoperoxidase staining with primary antibodies against RANTES, MCP-1, ICAM-1, and LF

24 Infected cells were also labeled with primary antibodies against the virus env surface protein

25 ucts was examined by Western blots using the primary antibody against 71-74 residues of cdLC1.

26 were sectioned, dewaxed, and incubated with primary antibody against TGF-beta(b)1 latency-associated

27 urfaces ready for covalent immobilization of primary antibodies and a strong bonding between PDMS sub

28 cultured, fixed, and incubated with specific primary antibodies and their corresponding labeled secon

29 dsorption was then assessed using a specific primary antibody and a secondary antibody conjugated wit

30 mmobilization of UPEC, bovine serum albumin, primary antibody and Horse Radish Peroxidase (HRP) tagge

31 ic antigen (CEA) was immobilized between the primary antibody and horseradish peroxidase (HRP)-conjug

32 he optimal concentration of coating antigen, primary antibody and secondary antibody.

33 All but two patients made primary antibody and T-cell proliferative responses to a

34 the importance of the connection between the primary antibody and the magnetic bead, we compared brid

35 nker chemistries were tried for reacting the primary antibody, and its response to target and nonspec

36 LPS from various species of bacteria and, as primary antibodies, anti-murein lipoprotein (MLP), pepti

37 The assay employing a primary antibodies arrayed on a CMC surface and detectio

38 f the particle and "intermediate" views, the primary antibody binding site is near the intersection b

39 Serine 15 (phospho-p53(15)), was captured by primary antibodies bound on magnetic Fe3O4 nanoparticles

40 formed between antigens and their respective primary antibodies by cupric ions at high pH.

41 Besides the initial screening of primary antibodies, collection of several hundreds of sa

42 lationship between cluster structure and the primary antibody-combining regions of the HA protein.

43 Primary antibody deficiencies represent the most prevale

44 plemented by more detailed incidence data on primary antibody deficiencies, revealing trends in diagn

45 new biomarker sets for further research into primary antibody deficiencies.

46 d conditions that lead to the development of primary antibody deficiencies.

47 knowledge on the pulmonary manifestations of primary antibody deficiency (PAD) syndromes in adults.

48 ough autoimmunity is common in patients with primary antibody deficiency (PAD), it remains unknown wh

49 n associated with infection in patients with primary antibody deficiency (PAD).

50 The primary antibody deficiency syndromes are a rare group o

51 ctivate PI3K signaling have been linked to a primary antibody deficiency.

52 the presence of this organism in 17 (19.3%) primary antibody-deficient (PAD) patients, 4 (5%) adults

53 ficiency (CVID) is the commonest symptomatic primary antibody disorder, with monogenic causes identif

54 These primary antibodies displayed evidence of diversity in al

55 agnostic antibody assay was performed with a primary antibody, double-labeled amplicons, and fluoroph

56 The resulting primary antibody elicits an anti-antibody response or an

57 ed by immunohistochemistry and the following primary antibodies evaluation.

58 scent molecule: mouse monoclonal anti-biotin primary antibody (fluorescein), biotin (B-phycoerythrin)

59 Specifically, we used a cocktail of primary antibodies for both epithelial and mesenchymal a

60 -bound tissue sections reacted with specific primary antibodies for rat 5-HT(1B, 1D) and (1F) recepto

61 r (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptame

62 of mouse IgG) decreased the affinity of the primary antibody for DCP-UO22+ by 4-fold.

63 Omission or preadsorption of primary antibodies from the antisera and subsequent incu

64 probings of the same membrane with different primary antibodies (> or = 12) and retention of strong s

65 nti-immune complex (IC) antibody binding the primary antibody-HT-2 toxin complex.

66 The detection of measles-specific primary antibodies (IgG) using electrochemical impedimet

67 or combined with carbon nanotubes (CNTs) for primary antibody immobilization to develop a simple and

68 ombinant human immunoglobulin G1 and used as primary antibodies in enzyme-linked immunosorbent assays

69 Primary antibodies included rabbit anti-mouse iNOS combi

70 ryosectioning and were stained using various primary antibodies, including anti-Lewis MHC class II (O

71 isolated compartments: (1) sample well, (2) primary antibody labeling well, (3) secondary antibody l

72 The recent development of large primary antibody libraries enables selection of antibodi

73 Control experiments involved omitting the primary antibodies; no labelling was visible under these

74 Protein target was sandwiched between the primary antibody of HBs (Ab1) immobilized on the MNPs an

75 First, the primary antibody of HBs (Ab1) was immobilized on the sur

76 -decorated universal quantum dots and intact primary antibodies, offers a fast, simple and purificati

77 easily and homogeneously coats the specific primary antibody on the polyvinylidene fluoride (PVDF) m

78 Profiles correlating primary antibody-producing cells with the molecular char

79 Furthermore, mixed BMT reconstituted the primary antibody production in BXSB recipients impressiv

80 Moreover, mixed BMT reconstituted primary antibody production in BXSB recipients, so that

81 atic hypermutation in the diversification of primary antibody repertoire in these animals.

82 In the bone marrow, diversity in the primary antibody repertoire is created by the combinator

83 In most vertebrates, a primary antibody repertoire is created through the recom

84 ts suggest that the binding potential of the primary antibody repertoire may be significantly expande

85 The limited primary antibody repertoire uses multiple mechanisms to

86 ugments the recombinational diversity of the primary antibody repertoire.

87 ociated with the structural diversity of the primary antibody repertoire.

88 to drive GALT development and diversify the primary antibody repertoire; however, the molecular mech

89 proaches to evaluate in depth the content of primary antibody repertoires and, ultimately, to study h

90 xons from germline gene segments to generate primary antibody repertoires.

91 to support the development both of a potent primary antibody response and of the germinal center res

92 c T-lymphocyte responses but does affect the primary antibody response and the generation of memory B

93 HIV-1 Envelope (Env) and characterizing the primary antibody response for HIV-1 neutralization.

94 odel of the early events that occur during a primary antibody response to a T cell-dependent antigen.

95 T cell help is selective and limiting to the primary antibody response to influenza virus infection a

96 At the same time, the primary antibody response to the H3N2 challenge virus wa

97 Although the primary antibody response to the PPS14-OVA conjugate exc

98 owing MZ B-cell reconstitution resulted in a primary antibody response, demonstrating that MZ B-cell

99 o provide help to wild-type B cells during a primary antibody response.

100 r efficacy, especially in eliciting a strong primary antibody response.

101 ion of Atg7 (B/Atg7(-/-) mice) showed normal primary antibody responses after immunization against in

102 find that IKKalpha(AA) B cells mount normal primary antibody responses but do not enter germinal cen

103 -70 varied over time, including increases in primary antibody responses late in the disease course.

104 Although BLPs enhanced the primary antibody responses seen in some children with no

105 ith the fusion protein gave rise to enhanced primary antibody responses to gp120, particularly of the

106 Although HIV-1-infected children showed good primary antibody responses to measles vaccine, their rap

107 immunized with NS3-FL developed high-titered primary antibody responses to the NS3 ATPase/ helicase d

108 with azithromycin led to significantly lower primary antibody responses, decreased recall proliferati

109 either cross-reactive antibodies to SV40 or primary antibodies resulting from SV40 infection.

110 Western blot analysis with the same primary antibody showed a specific positive band for iNO

111 ed with 2,4-dinitrophenylhydrazine (DNPH), a primary antibody specific for the 2,4-dinitrophenol grou

112 ue and its function in altered and humanized primary antibody structures.

113 ditionally, the FLISA utilizes 100-fold less primary antibody than the conventional immunoassay.

114 d to Sepharose beads, is used to capture the primary antibody (the antibody of interest).

115 Using a highly affine anti-DCF primary antibody, the optimized ULISA reached a detectio

116 hile conventional WB requires 0.4 mug of the primary antibody, the proposed technique only uses 4 x 1

117 hemistry with double immunolabeling, using a primary antibody to amino acids 1-10 of VEGF, together w

118 ctions between MCMV, a glycoprotein-specific primary antibody to MCMV, and polystyrene bead "anchors,

119 -1)) reducing at the same time the amount of primary antibody used (30,000 vs. 1000 dilution factor).

120 etecting a specific protein of interest with primary antibodies using automated fluorescence microsco

121 of the antigens recognized by the monoclonal primary antibodies was further confirmed by Western immu

122 le electrodes on a microfabricated chip, the primary antibody was selectively and covalently attached

123 Primary antibodies were immobilized on a solid substrate

124 Anti-SEB primary antibodies were immobilized onto the CNT surface

125 uidic channel, microarrays of five different primary antibodies were patterned onto a single channel

126 First, specific primary antibodies were separately bound to enzymes in c

127 After all primary antibodies were tested in positive and negative

128 PG21 anti-AR and anti-c-fos primary antibodies were visualized by fluorescence micro

129 ry antibody specific to the Fc region of the primary antibody, were used to affect virus mobility.

130 escribed was blocked by preabsorption of the primary antibodies with antigen.

131 ecificity was tested by preadsorption of the primary antibody with a peptide corresponding to sst2A(3

132 nvolves binding of the target protein with a primary antibody with high affinity and specificity, fol

133 ilized estrogen for the binding sites of the primary antibody, with subsequent revelation using alkal